TMIC-15. OMX IS A TUMOR MICROENVIRONMENT MODIFIER THAT RESTORES ANTI-TUMOR IMMUNITY AND IMPROVES ANTI-TUMOR EFFICACY BY REDUCING TUMOR HYPOXIA IN INTRACRANIAL GLIOBLASTOMA MOUSE MODEL Article Swipe
Natacha Le Moan
,
Tina Davis
,
Philberta Leung
,
Sarah Ng
,
Jonathan A. Winger
,
Stephen P. Cary
,
Nicholas Butowski
,
Ana Krtolica
·
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1093/neuonc/noy148.1074
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1093/neuonc/noy148.1074
Intratumoral hypoxia is associated with resistance to chemo- and radio-therapies and poor patient outcomes. In addition, hypoxia promotes the immune escape of tumors by altering the recruitment and function of innate and adaptive immune effector and suppressor cells. Therefore, reversing tumor hypoxia to create an immunopermissive microenvironment may improve anti-tumor response, and combined with immunotherapy approaches such as checkpoint inhibitors (CPI) may increase therapeutic efficacy. OMX, an anti-cancer therapy designed to reverse tumor hypoxia, efficiently accumulates in orthotopic rodent GB and spontaneous canine brain tumors, reduces tumor hypoxia and enhances immunotherapeutic efficacy. We used in vivo bioluminescence imaging of tumor, immunohistochemistry, flow cytometry, and cytokine multiplex assays to evaluate OMX’s ability to immunosensitize the GL261 brain tumor microenvironment and promote tumor cures. Following intravenous administration in brain tumor-bearing mice, OMX reduces tumor hypoxia, modulates the IFNg signaling pathway, enhances the infiltration of tumor-specific CX3CR1+ CD8 T cells into the tumor (using the EphA2 as a GL261-specific tumor antigen), increases the activation of cytotoxic T lymphocytes (CTLs), decreases Tim3 and Lag3 exhaustion markers on CD8 T cells, and reduces the number of immunosuppressive cells such as MDSCs and Tregs in the tumor. Similar immunological changes are observed when OMX is combined with anti-PD-1. In late-stage tumor-bearing mice, we observed a 40% tumor cure rate for the combination of OMX with anti-PD-1, while anti-PD-1 alone resulted only in 5% tumor cures. Following rechallenge with GL261 tumor cells injected on the other side of the brain, all mice treated with the combination of OMX with anti-PD-1 survived, indicating the presence of long-term immunological memory against glioma cells. By delivering oxygen specifically to the hypoxic tumor microenvironment, OMX may restore anti-cancer immune responses in GB patients and synergize with radiotherapy and immunotherapy to enhance tumor control and improve patient outcomes.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/neuonc/noy148.1074
- https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi259/26280951/noy148.1074.pdf
- OA Status
- bronze
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2899673325
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2899673325Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/neuonc/noy148.1074Digital Object Identifier
- Title
-
TMIC-15. OMX IS A TUMOR MICROENVIRONMENT MODIFIER THAT RESTORES ANTI-TUMOR IMMUNITY AND IMPROVES ANTI-TUMOR EFFICACY BY REDUCING TUMOR HYPOXIA IN INTRACRANIAL GLIOBLASTOMA MOUSE MODELWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2018Year of publication
- Publication date
-
2018-11-01Full publication date if available
- Authors
-
Natacha Le Moan, Tina Davis, Philberta Leung, Sarah Ng, Jonathan A. Winger, Stephen P. Cary, Nicholas Butowski, Ana KrtolicaList of authors in order
- Landing page
-
https://doi.org/10.1093/neuonc/noy148.1074Publisher landing page
- PDF URL
-
https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi259/26280951/noy148.1074.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi259/26280951/noy148.1074.pdfDirect OA link when available
- Concepts
-
Tumor microenvironment, Cancer research, Tumor hypoxia, Immunotherapy, Cytotoxic T cell, Immune system, Brain tumor, Medicine, CD8, Tumor-infiltrating lymphocytes, Glioma, Immunology, Pathology, Biology, Internal medicine, In vitro, Biochemistry, Radiation therapyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2899673325 |
|---|---|
| doi | https://doi.org/10.1093/neuonc/noy148.1074 |
| ids.doi | https://doi.org/10.1093/neuonc/noy148.1074 |
| ids.mag | 2899673325 |
| ids.openalex | https://openalex.org/W2899673325 |
| fwci | 0.0 |
| type | article |
| title | TMIC-15. OMX IS A TUMOR MICROENVIRONMENT MODIFIER THAT RESTORES ANTI-TUMOR IMMUNITY AND IMPROVES ANTI-TUMOR EFFICACY BY REDUCING TUMOR HYPOXIA IN INTRACRANIAL GLIOBLASTOMA MOUSE MODEL |
| biblio.issue | suppl_6 |
| biblio.volume | 20 |
| biblio.last_page | vi259 |
| biblio.first_page | vi259 |
| topics[0].id | https://openalex.org/T10631 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.998199999332428 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1306 |
| topics[0].subfield.display_name | Cancer Research |
| topics[0].display_name | Cancer, Hypoxia, and Metabolism |
| topics[1].id | https://openalex.org/T10129 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9907000064849854 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2716 |
| topics[1].subfield.display_name | Genetics |
| topics[1].display_name | Glioma Diagnosis and Treatment |
| topics[2].id | https://openalex.org/T12996 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9883999824523926 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1305 |
| topics[2].subfield.display_name | Biotechnology |
| topics[2].display_name | Cancer Research and Treatments |
| is_xpac | False |
| apc_list.value | 4612 |
| apc_list.currency | USD |
| apc_list.value_usd | 4612 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2776107976 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8029093742370605 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1786433 |
| concepts[0].display_name | Tumor microenvironment |
| concepts[1].id | https://openalex.org/C502942594 |
| concepts[1].level | 1 |
| concepts[1].score | 0.672309398651123 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[1].display_name | Cancer research |
| concepts[2].id | https://openalex.org/C2779081379 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6567749977111816 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q7852677 |
| concepts[2].display_name | Tumor hypoxia |
| concepts[3].id | https://openalex.org/C2777701055 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5500109791755676 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[3].display_name | Immunotherapy |
| concepts[4].id | https://openalex.org/C154317977 |
| concepts[4].level | 3 |
| concepts[4].score | 0.542049765586853 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q376266 |
| concepts[4].display_name | Cytotoxic T cell |
| concepts[5].id | https://openalex.org/C8891405 |
| concepts[5].level | 2 |
| concepts[5].score | 0.540717363357544 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[5].display_name | Immune system |
| concepts[6].id | https://openalex.org/C2779130545 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5332654714584351 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q233309 |
| concepts[6].display_name | Brain tumor |
| concepts[7].id | https://openalex.org/C71924100 |
| concepts[7].level | 0 |
| concepts[7].score | 0.5075279474258423 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[7].display_name | Medicine |
| concepts[8].id | https://openalex.org/C167672396 |
| concepts[8].level | 3 |
| concepts[8].score | 0.49330225586891174 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q417800 |
| concepts[8].display_name | CD8 |
| concepts[9].id | https://openalex.org/C2778326572 |
| concepts[9].level | 4 |
| concepts[9].score | 0.45605772733688354 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q7852668 |
| concepts[9].display_name | Tumor-infiltrating lymphocytes |
| concepts[10].id | https://openalex.org/C2778227246 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4233933091163635 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q1365309 |
| concepts[10].display_name | Glioma |
| concepts[11].id | https://openalex.org/C203014093 |
| concepts[11].level | 1 |
| concepts[11].score | 0.3221820592880249 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[11].display_name | Immunology |
| concepts[12].id | https://openalex.org/C142724271 |
| concepts[12].level | 1 |
| concepts[12].score | 0.31005486845970154 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[12].display_name | Pathology |
| concepts[13].id | https://openalex.org/C86803240 |
| concepts[13].level | 0 |
| concepts[13].score | 0.2211216390132904 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[13].display_name | Biology |
| concepts[14].id | https://openalex.org/C126322002 |
| concepts[14].level | 1 |
| concepts[14].score | 0.18214374780654907 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[14].display_name | Internal medicine |
| concepts[15].id | https://openalex.org/C202751555 |
| concepts[15].level | 2 |
| concepts[15].score | 0.11700144410133362 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[15].display_name | In vitro |
| concepts[16].id | https://openalex.org/C55493867 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[16].display_name | Biochemistry |
| concepts[17].id | https://openalex.org/C509974204 |
| concepts[17].level | 2 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q180507 |
| concepts[17].display_name | Radiation therapy |
| keywords[0].id | https://openalex.org/keywords/tumor-microenvironment |
| keywords[0].score | 0.8029093742370605 |
| keywords[0].display_name | Tumor microenvironment |
| keywords[1].id | https://openalex.org/keywords/cancer-research |
| keywords[1].score | 0.672309398651123 |
| keywords[1].display_name | Cancer research |
| keywords[2].id | https://openalex.org/keywords/tumor-hypoxia |
| keywords[2].score | 0.6567749977111816 |
| keywords[2].display_name | Tumor hypoxia |
| keywords[3].id | https://openalex.org/keywords/immunotherapy |
| keywords[3].score | 0.5500109791755676 |
| keywords[3].display_name | Immunotherapy |
| keywords[4].id | https://openalex.org/keywords/cytotoxic-t-cell |
| keywords[4].score | 0.542049765586853 |
| keywords[4].display_name | Cytotoxic T cell |
| keywords[5].id | https://openalex.org/keywords/immune-system |
| keywords[5].score | 0.540717363357544 |
| keywords[5].display_name | Immune system |
| keywords[6].id | https://openalex.org/keywords/brain-tumor |
| keywords[6].score | 0.5332654714584351 |
| keywords[6].display_name | Brain tumor |
| keywords[7].id | https://openalex.org/keywords/medicine |
| keywords[7].score | 0.5075279474258423 |
| keywords[7].display_name | Medicine |
| keywords[8].id | https://openalex.org/keywords/cd8 |
| keywords[8].score | 0.49330225586891174 |
| keywords[8].display_name | CD8 |
| keywords[9].id | https://openalex.org/keywords/tumor-infiltrating-lymphocytes |
| keywords[9].score | 0.45605772733688354 |
| keywords[9].display_name | Tumor-infiltrating lymphocytes |
| keywords[10].id | https://openalex.org/keywords/glioma |
| keywords[10].score | 0.4233933091163635 |
| keywords[10].display_name | Glioma |
| keywords[11].id | https://openalex.org/keywords/immunology |
| keywords[11].score | 0.3221820592880249 |
| keywords[11].display_name | Immunology |
| keywords[12].id | https://openalex.org/keywords/pathology |
| keywords[12].score | 0.31005486845970154 |
| keywords[12].display_name | Pathology |
| keywords[13].id | https://openalex.org/keywords/biology |
| keywords[13].score | 0.2211216390132904 |
| keywords[13].display_name | Biology |
| keywords[14].id | https://openalex.org/keywords/internal-medicine |
| keywords[14].score | 0.18214374780654907 |
| keywords[14].display_name | Internal medicine |
| keywords[15].id | https://openalex.org/keywords/in-vitro |
| keywords[15].score | 0.11700144410133362 |
| keywords[15].display_name | In vitro |
| language | en |
| locations[0].id | doi:10.1093/neuonc/noy148.1074 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S106908163 |
| locations[0].source.issn | 1522-8517, 1523-5866 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1522-8517 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Neuro-Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| locations[0].source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi259/26280951/noy148.1074.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Neuro-Oncology |
| locations[0].landing_page_url | https://doi.org/10.1093/neuonc/noy148.1074 |
| locations[1].id | pmh:oai:europepmc.org:5785797 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306400806 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | Europe PMC (PubMed Central) |
| locations[1].source.host_organization | https://openalex.org/I1303153112 |
| locations[1].source.host_organization_name | European Bioinformatics Institute |
| locations[1].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/6216340 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5012959704 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-1674-4720 |
| authorships[0].author.display_name | Natacha Le Moan |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210099232 |
| authorships[0].affiliations[0].raw_affiliation_string | Omniox, Inc, San Carlos, CA, USA |
| authorships[0].institutions[0].id | https://openalex.org/I4210099232 |
| authorships[0].institutions[0].ror | https://ror.org/011cheg80 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210099232 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Omniox (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Natacha Le Moan |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Omniox, Inc, San Carlos, CA, USA |
| authorships[1].author.id | https://openalex.org/A5045664700 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Tina Davis |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210099232 |
| authorships[1].affiliations[0].raw_affiliation_string | Omniox, Inc, San Carlos, CA, USA |
| authorships[1].institutions[0].id | https://openalex.org/I4210099232 |
| authorships[1].institutions[0].ror | https://ror.org/011cheg80 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210099232 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Omniox (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Tina Davis |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Omniox, Inc, San Carlos, CA, USA |
| authorships[2].author.id | https://openalex.org/A5113799086 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Philberta Leung |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210099232 |
| authorships[2].affiliations[0].raw_affiliation_string | Omniox, Inc, San Carlos, CA, USA |
| authorships[2].institutions[0].id | https://openalex.org/I4210099232 |
| authorships[2].institutions[0].ror | https://ror.org/011cheg80 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210099232 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Omniox (United States) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Philberta Leung |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Omniox, Inc, San Carlos, CA, USA |
| authorships[3].author.id | https://openalex.org/A5046831293 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-9307-4767 |
| authorships[3].author.display_name | Sarah Ng |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210099232 |
| authorships[3].affiliations[0].raw_affiliation_string | Omniox, Inc, San Carlos, CA, USA |
| authorships[3].institutions[0].id | https://openalex.org/I4210099232 |
| authorships[3].institutions[0].ror | https://ror.org/011cheg80 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210099232 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Omniox (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Sarah Ng |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Omniox, Inc, San Carlos, CA, USA |
| authorships[4].author.id | https://openalex.org/A5033050158 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-1413-3384 |
| authorships[4].author.display_name | Jonathan A. Winger |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210099232 |
| authorships[4].affiliations[0].raw_affiliation_string | Omniox, Inc, San Carlos, CA, USA |
| authorships[4].institutions[0].id | https://openalex.org/I4210099232 |
| authorships[4].institutions[0].ror | https://ror.org/011cheg80 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210099232 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Omniox (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jonathan Winger |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Omniox, Inc, San Carlos, CA, USA |
| authorships[5].author.id | https://openalex.org/A5112070179 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Stephen P. Cary |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210099232 |
| authorships[5].affiliations[0].raw_affiliation_string | Omniox, Inc, San Carlos, CA, USA |
| authorships[5].institutions[0].id | https://openalex.org/I4210099232 |
| authorships[5].institutions[0].ror | https://ror.org/011cheg80 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210099232 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Omniox (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Stephen Cary |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Omniox, Inc, San Carlos, CA, USA |
| authorships[6].author.id | https://openalex.org/A5090305344 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-5162-2406 |
| authorships[6].author.display_name | Nicholas Butowski |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I180670191 |
| authorships[6].affiliations[0].raw_affiliation_string | UC San Francisco, San Francisco, CA, USA |
| authorships[6].institutions[0].id | https://openalex.org/I180670191 |
| authorships[6].institutions[0].ror | https://ror.org/043mz5j54 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I180670191 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | University of California, San Francisco |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Nicholas Butowski |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | UC San Francisco, San Francisco, CA, USA |
| authorships[7].author.id | https://openalex.org/A5010037572 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Ana Krtolica |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210099232 |
| authorships[7].affiliations[0].raw_affiliation_string | Omniox, Inc, San Carlos, CA, USA |
| authorships[7].institutions[0].id | https://openalex.org/I4210099232 |
| authorships[7].institutions[0].ror | https://ror.org/011cheg80 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210099232 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Omniox (United States) |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Ana Krtolica |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Omniox, Inc, San Carlos, CA, USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi259/26280951/noy148.1074.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | TMIC-15. OMX IS A TUMOR MICROENVIRONMENT MODIFIER THAT RESTORES ANTI-TUMOR IMMUNITY AND IMPROVES ANTI-TUMOR EFFICACY BY REDUCING TUMOR HYPOXIA IN INTRACRANIAL GLIOBLASTOMA MOUSE MODEL |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10631 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.998199999332428 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1306 |
| primary_topic.subfield.display_name | Cancer Research |
| primary_topic.display_name | Cancer, Hypoxia, and Metabolism |
| related_works | https://openalex.org/W2234322404, https://openalex.org/W3208778134, https://openalex.org/W3005931108, https://openalex.org/W4386951147, https://openalex.org/W3010386727, https://openalex.org/W4312209854, https://openalex.org/W3187751359, https://openalex.org/W4385302966, https://openalex.org/W4382699865, https://openalex.org/W3112456455 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1093/neuonc/noy148.1074 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S106908163 |
| best_oa_location.source.issn | 1522-8517, 1523-5866 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1522-8517 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Neuro-Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| best_oa_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi259/26280951/noy148.1074.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Neuro-Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.1093/neuonc/noy148.1074 |
| primary_location.id | doi:10.1093/neuonc/noy148.1074 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S106908163 |
| primary_location.source.issn | 1522-8517, 1523-5866 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1522-8517 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Neuro-Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| primary_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi259/26280951/noy148.1074.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Neuro-Oncology |
| primary_location.landing_page_url | https://doi.org/10.1093/neuonc/noy148.1074 |
| publication_date | 2018-11-01 |
| publication_year | 2018 |
| referenced_works_count | 0 |
| abstract_inverted_index.T | 145, 163, 174 |
| abstract_inverted_index.a | 154, 208 |
| abstract_inverted_index.5% | 226 |
| abstract_inverted_index.By | 264 |
| abstract_inverted_index.GB | 79, 280 |
| abstract_inverted_index.In | 14, 202 |
| abstract_inverted_index.We | 92 |
| abstract_inverted_index.an | 44, 66 |
| abstract_inverted_index.as | 57, 153, 184 |
| abstract_inverted_index.by | 23 |
| abstract_inverted_index.in | 76, 94, 125, 188, 225, 279 |
| abstract_inverted_index.is | 2, 198 |
| abstract_inverted_index.of | 21, 29, 98, 141, 161, 180, 216, 240, 249, 257 |
| abstract_inverted_index.on | 172, 236 |
| abstract_inverted_index.to | 6, 42, 70, 107, 111, 268, 288 |
| abstract_inverted_index.we | 206 |
| abstract_inverted_index.40% | 209 |
| abstract_inverted_index.CD8 | 144, 173 |
| abstract_inverted_index.OMX | 129, 197, 217, 250, 273 |
| abstract_inverted_index.all | 243 |
| abstract_inverted_index.and | 8, 10, 27, 31, 35, 51, 80, 88, 103, 118, 168, 176, 186, 282, 286, 292 |
| abstract_inverted_index.are | 194 |
| abstract_inverted_index.for | 213 |
| abstract_inverted_index.may | 47, 61, 274 |
| abstract_inverted_index.the | 18, 25, 113, 134, 139, 148, 151, 159, 178, 189, 214, 237, 241, 247, 255, 269 |
| abstract_inverted_index.IFNg | 135 |
| abstract_inverted_index.Lag3 | 169 |
| abstract_inverted_index.OMX, | 65 |
| abstract_inverted_index.Tim3 | 167 |
| abstract_inverted_index.cure | 211 |
| abstract_inverted_index.flow | 101 |
| abstract_inverted_index.into | 147 |
| abstract_inverted_index.mice | 244 |
| abstract_inverted_index.only | 224 |
| abstract_inverted_index.poor | 11 |
| abstract_inverted_index.rate | 212 |
| abstract_inverted_index.side | 239 |
| abstract_inverted_index.such | 56, 183 |
| abstract_inverted_index.used | 93 |
| abstract_inverted_index.vivo | 95 |
| abstract_inverted_index.when | 196 |
| abstract_inverted_index.with | 4, 53, 200, 218, 231, 246, 251, 284 |
| abstract_inverted_index.(CPI) | 60 |
| abstract_inverted_index.EphA2 | 152 |
| abstract_inverted_index.GL261 | 114, 232 |
| abstract_inverted_index.MDSCs | 185 |
| abstract_inverted_index.Tregs | 187 |
| abstract_inverted_index.alone | 222 |
| abstract_inverted_index.brain | 83, 115, 126 |
| abstract_inverted_index.cells | 146, 182, 234 |
| abstract_inverted_index.mice, | 128, 205 |
| abstract_inverted_index.other | 238 |
| abstract_inverted_index.tumor | 40, 72, 86, 116, 120, 131, 149, 156, 210, 227, 233, 271, 290 |
| abstract_inverted_index.while | 220 |
| abstract_inverted_index.(using | 150 |
| abstract_inverted_index.assays | 106 |
| abstract_inverted_index.brain, | 242 |
| abstract_inverted_index.canine | 82 |
| abstract_inverted_index.cells, | 175 |
| abstract_inverted_index.cells. | 37, 263 |
| abstract_inverted_index.chemo- | 7 |
| abstract_inverted_index.create | 43 |
| abstract_inverted_index.cures. | 121, 228 |
| abstract_inverted_index.escape | 20 |
| abstract_inverted_index.glioma | 262 |
| abstract_inverted_index.immune | 19, 33, 277 |
| abstract_inverted_index.innate | 30 |
| abstract_inverted_index.memory | 260 |
| abstract_inverted_index.number | 179 |
| abstract_inverted_index.oxygen | 266 |
| abstract_inverted_index.rodent | 78 |
| abstract_inverted_index.tumor, | 99 |
| abstract_inverted_index.tumor. | 190 |
| abstract_inverted_index.tumors | 22 |
| abstract_inverted_index.(CTLs), | 165 |
| abstract_inverted_index.CX3CR1+ | 143 |
| abstract_inverted_index.OMX’s | 109 |
| abstract_inverted_index.Similar | 191 |
| abstract_inverted_index.ability | 110 |
| abstract_inverted_index.against | 261 |
| abstract_inverted_index.changes | 193 |
| abstract_inverted_index.control | 291 |
| abstract_inverted_index.enhance | 289 |
| abstract_inverted_index.hypoxia | 1, 16, 41, 87 |
| abstract_inverted_index.hypoxic | 270 |
| abstract_inverted_index.imaging | 97 |
| abstract_inverted_index.improve | 48, 293 |
| abstract_inverted_index.markers | 171 |
| abstract_inverted_index.patient | 12, 294 |
| abstract_inverted_index.promote | 119 |
| abstract_inverted_index.reduces | 85, 130, 177 |
| abstract_inverted_index.restore | 275 |
| abstract_inverted_index.reverse | 71 |
| abstract_inverted_index.therapy | 68 |
| abstract_inverted_index.treated | 245 |
| abstract_inverted_index.tumors, | 84 |
| abstract_inverted_index.adaptive | 32 |
| abstract_inverted_index.altering | 24 |
| abstract_inverted_index.combined | 52, 199 |
| abstract_inverted_index.cytokine | 104 |
| abstract_inverted_index.designed | 69 |
| abstract_inverted_index.effector | 34 |
| abstract_inverted_index.enhances | 89, 138 |
| abstract_inverted_index.evaluate | 108 |
| abstract_inverted_index.function | 28 |
| abstract_inverted_index.hypoxia, | 73, 132 |
| abstract_inverted_index.increase | 62 |
| abstract_inverted_index.injected | 235 |
| abstract_inverted_index.observed | 195, 207 |
| abstract_inverted_index.pathway, | 137 |
| abstract_inverted_index.patients | 281 |
| abstract_inverted_index.presence | 256 |
| abstract_inverted_index.promotes | 17 |
| abstract_inverted_index.resulted | 223 |
| abstract_inverted_index.Following | 122, 229 |
| abstract_inverted_index.addition, | 15 |
| abstract_inverted_index.anti-PD-1 | 221, 252 |
| abstract_inverted_index.antigen), | 157 |
| abstract_inverted_index.cytotoxic | 162 |
| abstract_inverted_index.decreases | 166 |
| abstract_inverted_index.efficacy. | 64, 91 |
| abstract_inverted_index.increases | 158 |
| abstract_inverted_index.long-term | 258 |
| abstract_inverted_index.modulates | 133 |
| abstract_inverted_index.multiplex | 105 |
| abstract_inverted_index.outcomes. | 13, 295 |
| abstract_inverted_index.response, | 50 |
| abstract_inverted_index.responses | 278 |
| abstract_inverted_index.reversing | 39 |
| abstract_inverted_index.signaling | 136 |
| abstract_inverted_index.survived, | 253 |
| abstract_inverted_index.synergize | 283 |
| abstract_inverted_index.Therefore, | 38 |
| abstract_inverted_index.activation | 160 |
| abstract_inverted_index.anti-PD-1, | 219 |
| abstract_inverted_index.anti-PD-1. | 201 |
| abstract_inverted_index.anti-tumor | 49 |
| abstract_inverted_index.approaches | 55 |
| abstract_inverted_index.associated | 3 |
| abstract_inverted_index.checkpoint | 58 |
| abstract_inverted_index.cytometry, | 102 |
| abstract_inverted_index.delivering | 265 |
| abstract_inverted_index.exhaustion | 170 |
| abstract_inverted_index.indicating | 254 |
| abstract_inverted_index.inhibitors | 59 |
| abstract_inverted_index.late-stage | 203 |
| abstract_inverted_index.orthotopic | 77 |
| abstract_inverted_index.resistance | 5 |
| abstract_inverted_index.suppressor | 36 |
| abstract_inverted_index.accumulates | 75 |
| abstract_inverted_index.anti-cancer | 67, 276 |
| abstract_inverted_index.combination | 215, 248 |
| abstract_inverted_index.efficiently | 74 |
| abstract_inverted_index.intravenous | 123 |
| abstract_inverted_index.lymphocytes | 164 |
| abstract_inverted_index.rechallenge | 230 |
| abstract_inverted_index.recruitment | 26 |
| abstract_inverted_index.spontaneous | 81 |
| abstract_inverted_index.therapeutic | 63 |
| abstract_inverted_index.Intratumoral | 0 |
| abstract_inverted_index.infiltration | 140 |
| abstract_inverted_index.radiotherapy | 285 |
| abstract_inverted_index.specifically | 267 |
| abstract_inverted_index.immunological | 192, 259 |
| abstract_inverted_index.immunotherapy | 54, 287 |
| abstract_inverted_index.tumor-bearing | 127, 204 |
| abstract_inverted_index.GL261-specific | 155 |
| abstract_inverted_index.administration | 124 |
| abstract_inverted_index.tumor-specific | 142 |
| abstract_inverted_index.bioluminescence | 96 |
| abstract_inverted_index.immunosensitize | 112 |
| abstract_inverted_index.radio-therapies | 9 |
| abstract_inverted_index.immunopermissive | 45 |
| abstract_inverted_index.microenvironment | 46, 117 |
| abstract_inverted_index.immunosuppressive | 181 |
| abstract_inverted_index.immunotherapeutic | 90 |
| abstract_inverted_index.microenvironment, | 272 |
| abstract_inverted_index.immunohistochemistry, | 100 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 8 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6000000238418579 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.15141327 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |